Pervasis Therapeutics Inc

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

26 documents for Pervasis Therapeutics Inc

- Pervasis Therapeutics, Inc. Named to Red Herring 100, Spring 2007.
Pioneer in regenerative cell-based therapies named to magazine's list of the 100 "Most Promising" companies driving the future of technology CAMBRID...
- Business Wire
- May 15, 2007
- Pervasis Therapeutics, Inc. Selected as a Finalist for the Red Herring 100 North America 2007.
Award Recognizes the 100 "Most Promising" Companies Driving the Future of Technology CAMBRIDGE, Mass. -- Red Herring today announced that Pervasis T...
- Business Wire
- April 17, 2007
- Pervasis Therapeutics Presents Promising Preclinical Data for its Minimally Invasive Cell Therapy at the European Association of Percutaneous Cardiovascular Interventions Annual Congress (EuroPCR).
Study Findings Show Treatment with PVS-10200 Following Angioplasty and Stent Placement for Peripheral Artery Disease in a Porcine Model Reduces Intima...
- Business Wire
- May 19, 2009

- SAS[R] Powers Small, Midsize Biotech and Pharmaceutical Companies.
..., Aids Vaccine Initiative Inc., Alba Therapeutics Corp., Alita Pharmaceuticals Inc.,Arca Biopharma, ...., QuatRx Pharmaceuticals Co., Sapphire Pervasis Therapeutics Inc., Soal Pharmtech Solutions LLC., ...
- Business Wire
- March 18, 2009
- Pervasis Therapeutics Closes Additional $9.75 Million in Financing.
Pioneer in regenerative cell-based therapies and devices announces additional funding in support of Vascugel[R] blood vessel repair therapeutic clinic...
- Business Wire
- January 15, 2008
- Pervasis Therapeutics Appoints Life Sciences Industry Executive Frederic Chereau as Company's President and Chief Executive Officer.
Former General Manager of Genzyme Cardiovascular Will Lead Company in Continued Development of Novel, Cell-Based Therapies to Treat Complex Diseases a...
- Business Wire
- October 21, 2008
- Pervasis Therapeutics Announces Successful Initial Safety Results of Phase I Trials of Vascugel(TM) Cell-Based Gel to Repair Arteries.
Pioneer in Regenerative Cell-Based Therapies and Devices Announces All Primary Endpoints of Safety Trial Achieved with No Significant Immunological Is...
- Business Wire
- November 15, 2006
- Pervasis Therapeutics Granted Orphan Drug Designation for Vascugel[R].
CAMBRIDGE, Mass. -- Pervasis Therapeutics, Inc., a biotechnology company pioneering biologically active cellular therapies to treat vascular and other...
- Business Wire
- May 05, 2009
- Pervasis Therapeutics Appoints Frank Litvack, M.D., Former CEO of Conor Medsystems, to its Board of Directors.
CAMBRIDGE, Mass. -- Pervasis Therapeutics, Inc., a biotechnology company pioneering regenerative biologically active therapies and devices to treat se...
- Business Wire
- August 05, 2008
- Pervasis Therapeutics Announces Promising Efficacy Results from Phase 1 and 2 Clinical Trials of Vascugel[R] in Dialysis Patients Needing Permanent AV Access, Data Builds on Compelling Safety Findings.
New Efficacy Data for Novel Therapy Highlighting Improved Patency, Vein Remodeling and Lumen Diameter for Patients Needing AV Access Will Be Presented...
- Business Wire
- November 19, 2008